| Name | NP-313 |
| Description | NP-313 (NSC-4264) is a potent antithrombotic agent that inhibits platelet aggregation and activation by inhibiting thromboxane A 2 synthesis and selectively inhibiting SOCC-mediated Ca2+ efflux. |
| In vitro | NP-313 (0-80 μM) inhibits platelet aggregation in a dose-dependent manner, reducing thrombin- and A23187-induced aggregation by up to 80% and 60%, respectively.[1] At concentrations of 0-8 μM, NP-313 concentration-dependently inhibits P-selectin expression and collagen- or thrombin-induced thromboxane B2 (TXB2) production in human platelets, and inhibits COX-1 and TXA2 synthase with IC50 values of 1.5 and 3.9 μM, respectively.[1] |
| In vivo | NP-313 (4-16 µg/g; i.v.) significantly prolongs time-to-occlusion (TTO), prolongs bleeding time, and inhibits platelet aggregation induced by collagen (10 µg/mL) in male ICR mice.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (240.34 mM), Sonication is recommended.
|
| Keywords | Thromboxane A2 synthetase | NP-313 | NP313 | CalciumChannel | Calcium Channel |
| Inhibitors Related | Quadrol | Tricaine methanesulfonate | 2,4,6-Tri-tert-butylphenol | Chlorocresol | L-Ascorbic acid | AEBSF hydrochloride | Heparin sodium salt | L-Ascorbic acid sodium salt | 2-Nitrobenzoic acid | Magnesium Chloride Hexahydrate | Magnesium sulfate | p-Hydroxycinnamic acid |
| Related Compound Libraries | Cysteine Covalent Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Protease Inhibitor Library | Calcium Channel Compound Library | Multi-Target Compound Library | Anti-Cardiovascular Disease Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Ion Channel Targeted Library |